Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Kathryn Zolman"'
Autor:
Jennifer R. Diamond, S. G. Eckhardt, Todd M. Pitts, Adrie van Bokhoven, Dara Aisner, Daniel L. Gustafson, Anna Capasso, Sharon Sams, Peter Kabos, Kathryn Zolman, Tiffany Colvin, Anthony D. Elias, Anna M. Storniolo, Bryan P. Schneider, Dexiang Gao, John J. Tentler, Virginia F. Borges, Kathy D. Miller
Publikováno v:
Breast Cancer Research, Vol 20, Iss 1, Pp 1-10 (2018)
Abstract Background Triple-negative breast cancer (TNBC) remains an aggressive breast cancer subtype with limited treatment options. ENMD-2076 is a small-molecule inhibitor of Aurora and angiogenic kinases with proapoptotic and antiproliferative acti
Externí odkaz:
https://doaj.org/article/b8114fdcf25045a88513879cfaf4520b
Autor:
Claire Ihle, Desiree Straign, Johana Canari, Kathleen Torkko, Kathryn Zolman, Erin Smith, Philip Owens
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa6383a609eb562aa82bd8c08d9be96e
https://doi.org/10.1136/jitc-2022-sitc2022.1448
https://doi.org/10.1136/jitc-2022-sitc2022.1448
Autor:
Anthony D. Elias, Alyse Staley, Monica Fornier, Gregory A. Vidal, Sharon Sams, Nicole Spoelstra, Peter Kabos, Jennifer R. Diamond, Elena Shagisultanova, Rosa I. Gallagher, Julia Wulfkuhle, Emanuel Petricoin, Kathryn Zolman, Stephanie Biller, Vida Alami, Tessa McSpadden, Virginia Borges, Lyndsey S. Crump, Dexiang Gao, Jennifer K. Richer
Publikováno v:
Cancer Research. 83:CT144-CT144
Background: Most estrogen receptor alpha positive (ER+) breast cancers (BCs) express androgen receptor (AR) protein, but its function is unclear. High AR relative to ER is associated with endocrine resistance. This randomized phase II trial of neoadj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85340548b90a85832ba4e5ded420688f
https://doi.org/10.1158/1538-7445.am2023-ct144
https://doi.org/10.1158/1538-7445.am2023-ct144
Autor:
Dexiang Gao, Tessa McSpadden, Sharon Sams, Anthony D. Elias, Virginia F. Borges, Julia Wulfkuhle, Anosheh Afghahi, Emanuel F. Petricoin, Jose I. Mayordomo, Stephanie Armstead, Jennifer R. Diamond, Nicole Spoelsta, Gregory A. Vidal, Elena Shagisultanova, Peter Kabos, Jennifer K. Richer, Lisa Carter, Monica Fournier, Gloria Crawford, Alyse Winchester, Kathryn Zolman
Publikováno v:
Cancer Research. 81:PS12-06
Background: Almost all ER+ breast cancers express androgen receptor (AR), but its function is uncertain. AR expression is associated with more indolent tumors, however high AR expression relative to ER is associated with endocrine resistance, and in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce5e95c71bea853f203f093c045b5b55
https://doi.org/10.1158/1538-7445.sabcs20-ps12-06
https://doi.org/10.1158/1538-7445.sabcs20-ps12-06
Autor:
Jose I. Mayordomo, Gloria Crawford, Virginia F. Borges, Gregory A. Vidal, Alyse Winchester, Kathryn Zolman, Elena Shagisultanova, Stephanie Armstead, Jennifer K. Richer, Lisa Carter, Dexiang Gao, Anosheh Afghahi, Sharon Sams, Emanuel F. Petricoin, Tessa McSpadden, Peter Kabos, Nicole Spoelsta, Anthony D. Elias, Julia Wulfkuhle, Jennifer R. Diamond
Publikováno v:
Cancer Research. 81:PS12-14
Up to 91% of ER+ breast cancers express androgen receptor (AR), but its function is uncertain. Although AR expression is associated with more indolent tumors, high AR expression relative to ER is associated with endocrine resistance, and in the absen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd471d9d872afdb58daaf362329e009b
https://doi.org/10.1158/1538-7445.sabcs20-ps12-14
https://doi.org/10.1158/1538-7445.sabcs20-ps12-14
Autor:
S.G. Eckhardt, Kathy D. Miller, Dara L. Aisner, Jennifer R. Diamond, Daniel L. Gustafson, Virginia F. Borges, Todd M. Pitts, Anna Capasso, Anthony D. Elias, Adrie van Bokhoven, Kathryn Zolman, Sharon Sams, Peter Kabos, Bryan P. Schneider, Dexiang Gao, Tiffany Colvin, John J. Tentler, Anna Maria Storniolo
Publikováno v:
Breast Cancer Research : BCR
Breast Cancer Research, Vol 20, Iss 1, Pp 1-10 (2018)
Breast Cancer Research, Vol 20, Iss 1, Pp 1-10 (2018)
Background Triple-negative breast cancer (TNBC) remains an aggressive breast cancer subtype with limited treatment options. ENMD-2076 is a small-molecule inhibitor of Aurora and angiogenic kinases with proapoptotic and antiproliferative activity in p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::015b0995a87dc3e392dd9853001e06a7
http://europepmc.org/articles/PMC6090978
http://europepmc.org/articles/PMC6090978